Fabrizio Vincenzi
Overview
Explore the profile of Fabrizio Vincenzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
2242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fontana A, Bergantini L, Carullo G, Scalvini L, DAlessandro M, Papulino C, et al.
ACS Pharmacol Transl Sci
. 2025 Feb;
8(2):380-393.
PMID: 39974640
Idiopathic pulmonary fibrosis (IPF) is a rare interstitial lung disease typified by a progressive fibrosing phenotype. IPF has been associated with aberrant HDAC activity, particularly HDAC6. Combining synthetic and modeling...
2.
Merighi S, Nigro M, Travagli A, Fernandez M, Vincenzi F, Varani K, et al.
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684558
Alzheimer's disease (AD) is a neurodegenerative pathology covering about 70% of all cases of dementia. It is associated with neuroinflammation and neuronal cell death, which are involved in disease progression....
3.
Mariotto E, Canton M, Marchioro C, Brancale A, Hamel E, Varani K, et al.
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39062759
Because of synergism between tubulin and HDAC inhibitors, we used the pharmacophore fusion strategy to generate potential tubulin-HDAC dual inhibitors. Drug design was based on the introduction of a -hydroxyacrylamide...
4.
Carullo G, Rossi S, Giudice V, Pezzotta A, Chianese U, Scala P, et al.
ACS Pharmacol Transl Sci
. 2024 Jul;
7(7):2125-2142.
PMID: 39022363
Blood cancers encompass a group of diseases affecting the blood, bone marrow, or lymphatic system, representing the fourth most commonly diagnosed cancer worldwide. Leukemias are characterized by the dysregulated proliferation...
5.
Carullo G, Orsini N, Piano I, Pozzetti L, Papa A, Fontana A, et al.
J Med Chem
. 2024 Jul;
67(17):14946-14973.
PMID: 38961727
Inherited retinal diseases, which include retinitis pigmentosa, are a family of genetic disorders characterized by gradual rod-cone degeneration and vision loss, without effective pharmacological treatments. Experimental approaches aim to delay...
6.
Bedini A, Elisi G, Fanini F, Retini M, Scalvini L, Pasquini S, et al.
J Pineal Res
. 2024 Apr;
76(2):e12941.
PMID: 38606814
The labeled ligand commonly employed in competition binding studies for melatonin receptor ligands, 2-[I]iodomelatonin, showed slow dissociation with different half-lives at the two receptor subtypes. This may affect the operational...
7.
Rossi S, Tatangelo V, Dichiara M, Butini S, Gemma S, Brogi S, et al.
Biomed Pharmacother
. 2024 Apr;
174:116537.
PMID: 38579402
Chronic Lymphocytic Leukemia (CLL) patients have a defective expression of the proapoptotic protein p66Shc and of its transcriptional factor STAT4, which evoke molecular abnormalities, impairing apoptosis and worsening disease prognosis...
8.
Oliva P, Suresh R, Pasquini S, Salmaso V, Will E, Tosh D, et al.
ACS Med Chem Lett
. 2023 Dec;
14(12):1640-1646.
PMID: 38116442
A adenosine receptor (AAR) agonists have cerebroprotective, cardioprotective, antinociceptive, and other pharmaceutical applications. We explored the structure-activity relationship of 5-arylethynyl aminothiophenes as AAR positive allosteric modulators (PAMs). The derivatives were...
9.
Fernandez M, Nigro M, Travagli A, Pasquini S, Vincenzi F, Varani K, et al.
Pharmaceutics
. 2023 Oct;
15(10).
PMID: 37896201
The blood-brain barrier (BBB) is a biological barrier that protects the central nervous system (CNS) by ensuring an appropriate microenvironment. Brain microvascular endothelial cells (ECs) control the passage of molecules...
10.
Vincenzi F, Pasquini S, Contri C, Cappello M, Nigro M, Travagli A, et al.
Biomolecules
. 2023 Sep;
13(9).
PMID: 37759787
Adenosine receptors (ARs) are widely acknowledged pharmacological targets yet are still underutilized in clinical practice. Their ubiquitous distribution in almost all cells and tissues of the body makes them, on...